Abstract
Four new quinofuracins F – I were isolated from the culture broth of Staphylotrichum boninense PF1444. The structures of quinofuracins F – I were elucidated by extensive spectroscopic analysis. These quinofuracins induced tumor suppressor protein p53-dependent cell death in human glioblastoma LNZTA3 cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 2009;9:714–23.
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844–8.
Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, et al. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 2013;73:2587–97.
Rew Y, Sun D, Gonzalez-Lopez De Turiso F, Bartberger MD, Beck HP, Canon J, et al. Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem. 2012;55:4936–54.
Yu S, Qin D, Shangary S, Chen J, Wang G, Ding K, et al. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2009;52:7970–3.
Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D, et al. The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol Cancer Ther. 2015;14:649–58.
Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, et al. Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. Mol Cancer Ther. 2015;14:2249–59.
Kawata Y, Nagasaka K, Oda K, Makii C, Takeuchi M, Oki S, et al. Effect of murine double-minute 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys. Cancer Sci. 2020;111:3824–34.
Fang Y, Liao G, Yu B. Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives. Acta Pharm Sin B 2020;10:1253–78.
Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet. 1994;8:171–6.
Tatsuda D, Momose I, Someno T, Sawa R, Kubota Y, Iijima M, et al. Quinofuracins A−E, produced by the fungus Staphylotrichum boninense PF1444, show p53-dependent growth suppression. J Nat Prod. 2015;78:188–95.
Tatsuda D, Amemiya M, Sawa R, Sumiyoshi K, Watanabe T, Momose I, et al. Coccoquinones A and B, new anthraquinone derivatives produced by Staphylotrichum coccosporum PF1460. J Antibiot. 2016;69:176–8.
Yabe K, Matsuyama Y, Ando Y, Nakajima H, Hamasaki T. Stereochemistry during aflatoxin biosynthesis: conversion of norsolorinic acid to averufin. Appl Environ Microbiol. 1993;59:2486–92.
Hatsuda Y, Hamasaki T, Ishida M, Yoshikawa S. The structure of a new metabolite from Aspergillus versicolor. Agr Biol Chem. 1969;33:131–3.
Fredenhagen A, Hug P, Sauter H, Peter HH. Paeciloquinones A, B, C, D, E and F: new potent inhibitors of protein tyrosine kinase produced by Paecilomyces carneus. II. Characterization and structure determination. J Antibiot. 1995;48:199–204.
Acknowledgements
We are grateful to Ms Y Kubota and Dr K Iijima (BIKAKEN) for the measurements of NMR and MS spectroscopic data; Mr K Sumiyoshi, Ms N Sumida, and Ms K Kobayashi (Meiji Seika Pharma) for fermentation of quinofuracins; and Ms I Ohsawa and Ms T Miyazawa (BIKAKEN) for technical assistance. This work was supported by JSPS KAKENHI Grant Number JP19K07311.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Tatsuda, D., Amemiya, M., Sawa, R. et al. Quinofuracins F – I, new quinofuracin derivatives produced by Staphylotrichum boninense PF1444. J Antibiot 74, 758–762 (2021). https://doi.org/10.1038/s41429-021-00452-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41429-021-00452-z